| # | Title | Journal | Year | Citations |
|---|
| 1 | P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature | Pharmacogenetics and Genomics | 1996 | 2,629 |
| 2 | Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders | Pharmacogenetics and Genomics | 1996 | 1,681 |
| 3 | The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence | Pharmacogenetics and Genomics | 1997 | 1,055 |
| 4 | Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants | Pharmacogenetics and Genomics | 2004 | 850 |
| 5 | Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data | Pharmacogenetics and Genomics | 2002 | 646 |
| 6 | The genetic determinants of the CYP3A5 polymorphism | Pharmacogenetics and Genomics | 2001 | 608 |
| 7 | The role of the CFP2C9-Leu 359 allelic variant in the tolbutamide polymorphism | Pharmacogenetics and Genomics | 1996 | 600 |
| 8 | Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver | Pharmacogenetics and Genomics | 2001 | 556 |
| 9 | D2 dopamine receptor gene (DRD2) Taql A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele | Pharmacogenetics and Genomics | 1997 | 518 |
| 10 | Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9 | Pharmacogenetics and Genomics | 1994 | 494 |
| 11 | Biochemistry and molecular biology of the human CYP2C subfamily | Pharmacogenetics and Genomics | 1994 | 484 |
| 12 | Higher plant metabolism of xenobiotics: the ???green liver??? concept | Pharmacogenetics and Genomics | 1994 | 451 |
| 13 | Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid | Pharmacogenetics and Genomics | 2001 | 445 |
| 14 | The AH-receptor: genetics, structure and function | Pharmacogenetics and Genomics | 1993 | 434 |
| 15 | Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites | Pharmacogenetics and Genomics | 1992 | 411 |
| 16 | The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients | Pharmacogenetics and Genomics | 2004 | 409 |
| 17 | Nomenclature for human CYP2D6 alleles | Pharmacogenetics and Genomics | 1996 | 403 |
| 18 | Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes | Pharmacogenetics and Genomics | 2000 | 401 |
| 19 | Noninvasive tests of CYP3A enzymes | Pharmacogenetics and Genomics | 1994 | 393 |
| 20 | Comprehensive analysis of thiopurine S-methyltransferase phenotype–genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants | Pharmacogenetics and Genomics | 2004 | 393 |
| 21 | High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1) | Pharmacogenetics and Genomics | 2004 | 391 |
| 22 | Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method | Pharmacogenetics and Genomics | 2000 | 376 |
| 23 | MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity | Pharmacogenetics and Genomics | 2001 | 373 |
| 24 | Nomenclature for N-acetyltransferases | Pharmacogenetics and Genomics | 1995 | 369 |
| 25 | (null) | Pharmacogenetics and Genomics | 2003 | 367 |
| 26 | Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution | Pharmacogenetics and Genomics | 1997 | 365 |
| 27 | Ivermectin sensitivity in collies is associated with a deletion mutation of the mdr1 gene | Pharmacogenetics and Genomics | 2001 | 365 |
| 28 | Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene | Pharmacogenetics and Genomics | 2003 | 361 |
| 29 | The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells | Pharmacogenetics and Genomics | 2001 | 359 |
| 30 | The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations | Pharmacogenetics and Genomics | 1999 | 354 |
| 31 | CYP3A gene expression in human gut epithelium | Pharmacogenetics and Genomics | 1994 | 328 |
| 32 | Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations | Pharmacogenetics and Genomics | 1997 | 314 |
| 33 | Deposition of Alzheimer's ??-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans | Pharmacogenetics and Genomics | 2002 | 311 |
| 34 | Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1 | Pharmacogenetics and Genomics | 1992 | 306 |
| 35 | Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase) | Pharmacogenetics and Genomics | 2004 | 305 |
| 36 | Genetic association between sensitivity to warfarin and expression of CYP2C9*3 | Pharmacogenetics and Genomics | 1997 | 296 |
| 37 | Common allelic variants of cytochrome P4503A4 and their prevalence in different populations | Pharmacogenetics and Genomics | 2002 | 295 |
| 38 | The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants | Pharmacogenetics and Genomics | 2001 | 293 |
| 39 | A proposed nomenclature system for the cytosolic sulfotransferase (SULT) superfamily | Pharmacogenetics and Genomics | 2004 | 293 |
| 40 | A study of the dopamine D2 receptor gene in pathological gambling | Pharmacogenetics and Genomics | 1996 | 289 |
| 41 | A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels | Pharmacogenetics and Genomics | 2004 | 285 |
| 42 | Dopamine D2 receptor gene variants: association and linkage studies in impulsive-addictive-compulsive behaviour | Pharmacogenetics and Genomics | 1995 | 281 |
| 43 | Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population | Pharmacogenetics and Genomics | 1998 | 281 |
| 44 | Genetic analysis of the human cytochrome P450 CYP2C9 locus | Pharmacogenetics and Genomics | 1996 | 281 |
| 45 | Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians | Pharmacogenetics and Genomics | 2004 | 279 |
| 46 | Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity | Pharmacogenetics and Genomics | 2004 | 274 |
| 47 | Thirteen UDPglucuronosyltransferase genes are encoded at the human UGT1 gene complex locus | Pharmacogenetics and Genomics | 2001 | 273 |
| 48 | Effects of ethnicity on the distribution of clinically relevant endothelial nitric oxide variants | Pharmacogenetics and Genomics | 2001 | 270 |
| 49 | Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6 | Pharmacogenetics and Genomics | 2001 | 268 |
| 50 | Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy | Pharmacogenetics and Genomics | 1995 | 267 |
